nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—Angiotensin 2 Receptor Antagonists—Irbesartan—type 2 diabetes mellitus	0.153	0.54	CiPCiCtD
Valsartan—Angiotensin 2 Receptor Antagonists—Losartan—type 2 diabetes mellitus	0.13	0.459	CiPCiCtD
Valsartan—Irbesartan—type 2 diabetes mellitus	0.125	0.58	CrCtD
Valsartan—coronary artery disease—type 2 diabetes mellitus	0.0986	0.626	CtDrD
Valsartan—Losartan—type 2 diabetes mellitus	0.0906	0.42	CrCtD
Valsartan—hypertension—type 2 diabetes mellitus	0.0588	0.374	CtDrD
Valsartan—ALB—type 2 diabetes mellitus	0.031	1	CbGaD
Valsartan—AGTR1—Irbesartan—type 2 diabetes mellitus	0.0213	0.168	CbGbCtD
Valsartan—Forasartan—Irbesartan—type 2 diabetes mellitus	0.0192	0.139	CrCrCtD
Valsartan—Tasosartan—Irbesartan—type 2 diabetes mellitus	0.017	0.123	CrCrCtD
Valsartan—Olmesartan—Irbesartan—type 2 diabetes mellitus	0.0153	0.11	CrCrCtD
Valsartan—Irbesartan—Losartan—type 2 diabetes mellitus	0.0139	0.1	CrCrCtD
Valsartan—Forasartan—Losartan—type 2 diabetes mellitus	0.0139	0.1	CrCrCtD
Valsartan—Losartan—Irbesartan—type 2 diabetes mellitus	0.0139	0.1	CrCrCtD
Valsartan—AGTR1—Losartan—type 2 diabetes mellitus	0.0137	0.108	CbGbCtD
Valsartan—SLCO1B3—Pioglitazone—type 2 diabetes mellitus	0.0135	0.106	CbGbCtD
Valsartan—Candesartan—Irbesartan—type 2 diabetes mellitus	0.0128	0.0922	CrCrCtD
Valsartan—Tasosartan—Losartan—type 2 diabetes mellitus	0.0123	0.0887	CrCrCtD
Valsartan—Olmesartan—Losartan—type 2 diabetes mellitus	0.011	0.0797	CrCrCtD
Valsartan—Candesartan—Losartan—type 2 diabetes mellitus	0.00924	0.0667	CrCrCtD
Valsartan—SLCO1B1—Repaglinide—type 2 diabetes mellitus	0.0087	0.0684	CbGbCtD
Valsartan—SLCO1B1—Pioglitazone—type 2 diabetes mellitus	0.00787	0.0619	CbGbCtD
Valsartan—SLCO1B1—Rosiglitazone—type 2 diabetes mellitus	0.00726	0.0571	CbGbCtD
Valsartan—SLCO1B3—Losartan—type 2 diabetes mellitus	0.00633	0.0497	CbGbCtD
Valsartan—ALB—Gliclazide—type 2 diabetes mellitus	0.00507	0.0399	CbGbCtD
Valsartan—ALB—Repaglinide—type 2 diabetes mellitus	0.00477	0.0375	CbGbCtD
Valsartan—ALB—Rosiglitazone—type 2 diabetes mellitus	0.00398	0.0313	CbGbCtD
Valsartan—SLCO1B1—Losartan—type 2 diabetes mellitus	0.00368	0.029	CbGbCtD
Valsartan—ALB—Nateglinide—type 2 diabetes mellitus	0.00327	0.0257	CbGbCtD
Valsartan—CYP2C9—Glimepiride—type 2 diabetes mellitus	0.00321	0.0253	CbGbCtD
Valsartan—CYP2C9—Glipizide—type 2 diabetes mellitus	0.00294	0.0231	CbGbCtD
Valsartan—CYP2C9—Gliclazide—type 2 diabetes mellitus	0.00273	0.0215	CbGbCtD
Valsartan—CYP2C9—Pioglitazone—type 2 diabetes mellitus	0.00232	0.0183	CbGbCtD
Valsartan—CYP2C9—Chlorpropamide—type 2 diabetes mellitus	0.00232	0.0183	CbGbCtD
Valsartan—ALB—Glyburide—type 2 diabetes mellitus	0.00221	0.0173	CbGbCtD
Valsartan—CYP2C9—Rosiglitazone—type 2 diabetes mellitus	0.00214	0.0169	CbGbCtD
Valsartan—CYP2C9—Tolbutamide—type 2 diabetes mellitus	0.00207	0.0163	CbGbCtD
Valsartan—ALB—Losartan—type 2 diabetes mellitus	0.00202	0.0159	CbGbCtD
Valsartan—CYP2C9—Nateglinide—type 2 diabetes mellitus	0.00176	0.0138	CbGbCtD
Valsartan—CYP2C9—Irbesartan—type 2 diabetes mellitus	0.00169	0.0133	CbGbCtD
Valsartan—CYP2C9—Glyburide—type 2 diabetes mellitus	0.00119	0.00935	CbGbCtD
Valsartan—CYP2C9—Losartan—type 2 diabetes mellitus	0.00109	0.00855	CbGbCtD
Valsartan—Tasosartan—AGTR2—type 2 diabetes mellitus	0.000446	0.503	CrCbGaD
Valsartan—Irbesartan—EDNRA—type 2 diabetes mellitus	0.000152	0.172	CrCbGaD
Valsartan—AGTR1—artery—type 2 diabetes mellitus	0.00014	0.196	CbGeAlD
Valsartan—AGTR1—endothelium—type 2 diabetes mellitus	0.000118	0.166	CbGeAlD
Valsartan—Olmesartan—ABCC2—type 2 diabetes mellitus	8.02e-05	0.0904	CrCbGaD
Valsartan—AGTR1—nephron tubule—type 2 diabetes mellitus	5.43e-05	0.076	CbGeAlD
Valsartan—SLCO1B3—liver—type 2 diabetes mellitus	4.97e-05	0.0696	CbGeAlD
Valsartan—AGTR1—cardiovascular system—type 2 diabetes mellitus	4.87e-05	0.0683	CbGeAlD
Valsartan—AGTR1—kidney—type 2 diabetes mellitus	4.77e-05	0.0668	CbGeAlD
Valsartan—AGTR1—cortex of kidney—type 2 diabetes mellitus	4.64e-05	0.065	CbGeAlD
Valsartan—SLCO1B1—kidney—type 2 diabetes mellitus	4.55e-05	0.0637	CbGeAlD
Valsartan—AGTR1—adipose tissue—type 2 diabetes mellitus	4.3e-05	0.0602	CbGeAlD
Valsartan—Tasosartan—CYP3A4—type 2 diabetes mellitus	4.2e-05	0.0473	CrCbGaD
Valsartan—Irbesartan—CYP1A2—type 2 diabetes mellitus	4.17e-05	0.0469	CrCbGaD
Valsartan—Losartan—ACE—type 2 diabetes mellitus	3.78e-05	0.0426	CrCbGaD
Valsartan—AGTR1—liver—type 2 diabetes mellitus	3.01e-05	0.0422	CbGeAlD
Valsartan—SLCO1B1—liver—type 2 diabetes mellitus	2.87e-05	0.0403	CbGeAlD
Valsartan—Irbesartan—CYP3A4—type 2 diabetes mellitus	2.76e-05	0.0311	CrCbGaD
Valsartan—Losartan—CYP1A2—type 2 diabetes mellitus	2.68e-05	0.0302	CrCbGaD
Valsartan—Insomnia—Gliclazide—type 2 diabetes mellitus	2.39e-05	0.000756	CcSEcCtD
Valsartan—Infection—Orlistat—type 2 diabetes mellitus	2.38e-05	0.000753	CcSEcCtD
Valsartan—Loss of consciousness—Metformin—type 2 diabetes mellitus	2.38e-05	0.000753	CcSEcCtD
Valsartan—Paraesthesia—Gliclazide—type 2 diabetes mellitus	2.37e-05	0.00075	CcSEcCtD
Valsartan—Flatulence—Losartan—type 2 diabetes mellitus	2.37e-05	0.000749	CcSEcCtD
Valsartan—Hepatitis—Ramipril—type 2 diabetes mellitus	2.37e-05	0.000749	CcSEcCtD
Valsartan—Dizziness—Glimepiride—type 2 diabetes mellitus	2.36e-05	0.000746	CcSEcCtD
Valsartan—Dysgeusia—Losartan—type 2 diabetes mellitus	2.36e-05	0.000745	CcSEcCtD
Valsartan—Dyspnoea—Gliclazide—type 2 diabetes mellitus	2.36e-05	0.000745	CcSEcCtD
Valsartan—Nervous system disorder—Orlistat—type 2 diabetes mellitus	2.35e-05	0.000744	CcSEcCtD
Valsartan—Dizziness—Sitagliptin—type 2 diabetes mellitus	2.35e-05	0.000744	CcSEcCtD
Valsartan—Somnolence—Gliclazide—type 2 diabetes mellitus	2.35e-05	0.000743	CcSEcCtD
Valsartan—CYP2C9—cardiovascular system—type 2 diabetes mellitus	2.35e-05	0.0329	CbGeAlD
Valsartan—Urticaria—Glyburide—type 2 diabetes mellitus	2.34e-05	0.000739	CcSEcCtD
Valsartan—Angioedema—Irbesartan—type 2 diabetes mellitus	2.34e-05	0.000738	CcSEcCtD
Valsartan—Skin disorder—Orlistat—type 2 diabetes mellitus	2.33e-05	0.000737	CcSEcCtD
Valsartan—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	2.33e-05	0.000736	CcSEcCtD
Valsartan—Back pain—Losartan—type 2 diabetes mellitus	2.33e-05	0.000736	CcSEcCtD
Valsartan—Abdominal pain—Glyburide—type 2 diabetes mellitus	2.33e-05	0.000735	CcSEcCtD
Valsartan—Dyspepsia—Gliclazide—type 2 diabetes mellitus	2.33e-05	0.000735	CcSEcCtD
Valsartan—ALB—liver—type 2 diabetes mellitus	2.32e-05	0.0326	CbGeAlD
Valsartan—Muscle spasms—Losartan—type 2 diabetes mellitus	2.31e-05	0.000731	CcSEcCtD
Valsartan—Asthenia—Bromocriptine—type 2 diabetes mellitus	2.31e-05	0.00073	CcSEcCtD
Valsartan—Myalgia—Metformin—type 2 diabetes mellitus	2.31e-05	0.000729	CcSEcCtD
Valsartan—Chest pain—Metformin—type 2 diabetes mellitus	2.31e-05	0.000729	CcSEcCtD
Valsartan—Vertigo—Irbesartan—type 2 diabetes mellitus	2.3e-05	0.000726	CcSEcCtD
Valsartan—Headache—Pioglitazone—type 2 diabetes mellitus	2.3e-05	0.000726	CcSEcCtD
Valsartan—Syncope—Irbesartan—type 2 diabetes mellitus	2.29e-05	0.000725	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	2.29e-05	0.000724	CcSEcCtD
Valsartan—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	2.28e-05	0.000721	CcSEcCtD
Valsartan—Fatigue—Gliclazide—type 2 diabetes mellitus	2.28e-05	0.00072	CcSEcCtD
Valsartan—Nausea—Glipizide—type 2 diabetes mellitus	2.27e-05	0.000718	CcSEcCtD
Valsartan—Vomiting—Glimepiride—type 2 diabetes mellitus	2.27e-05	0.000717	CcSEcCtD
Valsartan—Vision blurred—Losartan—type 2 diabetes mellitus	2.27e-05	0.000717	CcSEcCtD
Valsartan—Vomiting—Sitagliptin—type 2 diabetes mellitus	2.26e-05	0.000715	CcSEcCtD
Valsartan—Constipation—Gliclazide—type 2 diabetes mellitus	2.26e-05	0.000714	CcSEcCtD
Valsartan—Rash—Glimepiride—type 2 diabetes mellitus	2.25e-05	0.000711	CcSEcCtD
Valsartan—Dermatitis—Glimepiride—type 2 diabetes mellitus	2.25e-05	0.000711	CcSEcCtD
Valsartan—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	2.25e-05	0.00071	CcSEcCtD
Valsartan—Rash—Sitagliptin—type 2 diabetes mellitus	2.24e-05	0.000709	CcSEcCtD
Valsartan—Dermatitis—Sitagliptin—type 2 diabetes mellitus	2.24e-05	0.000708	CcSEcCtD
Valsartan—Headache—Glimepiride—type 2 diabetes mellitus	2.24e-05	0.000707	CcSEcCtD
Valsartan—Cough—Irbesartan—type 2 diabetes mellitus	2.23e-05	0.000705	CcSEcCtD
Valsartan—Headache—Sitagliptin—type 2 diabetes mellitus	2.23e-05	0.000705	CcSEcCtD
Valsartan—Oedema—Metformin—type 2 diabetes mellitus	2.21e-05	0.000699	CcSEcCtD
Valsartan—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	2.2e-05	0.000696	CcSEcCtD
Valsartan—Angioedema—Losartan—type 2 diabetes mellitus	2.2e-05	0.000695	CcSEcCtD
Valsartan—Infection—Metformin—type 2 diabetes mellitus	2.2e-05	0.000694	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	2.19e-05	0.000691	CcSEcCtD
Valsartan—Arthralgia—Irbesartan—type 2 diabetes mellitus	2.18e-05	0.000688	CcSEcCtD
Valsartan—Myalgia—Irbesartan—type 2 diabetes mellitus	2.18e-05	0.000688	CcSEcCtD
Valsartan—Chest pain—Irbesartan—type 2 diabetes mellitus	2.18e-05	0.000688	CcSEcCtD
Valsartan—Shock—Metformin—type 2 diabetes mellitus	2.18e-05	0.000688	CcSEcCtD
Valsartan—Insomnia—Orlistat—type 2 diabetes mellitus	2.17e-05	0.000686	CcSEcCtD
Valsartan—Anxiety—Irbesartan—type 2 diabetes mellitus	2.17e-05	0.000686	CcSEcCtD
Valsartan—Hypersensitivity—Glyburide—type 2 diabetes mellitus	2.17e-05	0.000685	CcSEcCtD
Valsartan—Nervous system disorder—Metformin—type 2 diabetes mellitus	2.17e-05	0.000685	CcSEcCtD
Valsartan—Thrombocytopenia—Metformin—type 2 diabetes mellitus	2.16e-05	0.000684	CcSEcCtD
Valsartan—Vertigo—Losartan—type 2 diabetes mellitus	2.16e-05	0.000683	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	2.16e-05	0.000683	CcSEcCtD
Valsartan—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	2.16e-05	0.000683	CcSEcCtD
Valsartan—Syncope—Losartan—type 2 diabetes mellitus	2.16e-05	0.000682	CcSEcCtD
Valsartan—Paraesthesia—Orlistat—type 2 diabetes mellitus	2.15e-05	0.000681	CcSEcCtD
Valsartan—Skin disorder—Metformin—type 2 diabetes mellitus	2.15e-05	0.000679	CcSEcCtD
Valsartan—Immune system disorder—Ramipril—type 2 diabetes mellitus	2.14e-05	0.000677	CcSEcCtD
Valsartan—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	2.14e-05	0.000675	CcSEcCtD
Valsartan—Dizziness—Bromocriptine—type 2 diabetes mellitus	2.13e-05	0.000673	CcSEcCtD
Valsartan—Dry mouth—Irbesartan—type 2 diabetes mellitus	2.13e-05	0.000673	CcSEcCtD
Valsartan—Palpitations—Losartan—type 2 diabetes mellitus	2.13e-05	0.000672	CcSEcCtD
Valsartan—Nausea—Glimepiride—type 2 diabetes mellitus	2.12e-05	0.00067	CcSEcCtD
Valsartan—Loss of consciousness—Losartan—type 2 diabetes mellitus	2.11e-05	0.000669	CcSEcCtD
Valsartan—Nausea—Sitagliptin—type 2 diabetes mellitus	2.11e-05	0.000668	CcSEcCtD
Valsartan—Dyspepsia—Orlistat—type 2 diabetes mellitus	2.11e-05	0.000668	CcSEcCtD
Valsartan—Asthenia—Glyburide—type 2 diabetes mellitus	2.11e-05	0.000668	CcSEcCtD
Valsartan—Anorexia—Metformin—type 2 diabetes mellitus	2.11e-05	0.000666	CcSEcCtD
Valsartan—Cough—Losartan—type 2 diabetes mellitus	2.1e-05	0.000664	CcSEcCtD
Valsartan—Urticaria—Gliclazide—type 2 diabetes mellitus	2.1e-05	0.000664	CcSEcCtD
Valsartan—Alopecia—Ramipril—type 2 diabetes mellitus	2.09e-05	0.000662	CcSEcCtD
Valsartan—Abdominal pain—Gliclazide—type 2 diabetes mellitus	2.09e-05	0.00066	CcSEcCtD
Valsartan—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	2.09e-05	0.00066	CcSEcCtD
Valsartan—Oedema—Irbesartan—type 2 diabetes mellitus	2.09e-05	0.00066	CcSEcCtD
Valsartan—Decreased appetite—Orlistat—type 2 diabetes mellitus	2.09e-05	0.000659	CcSEcCtD
Valsartan—Pruritus—Glyburide—type 2 diabetes mellitus	2.08e-05	0.000658	CcSEcCtD
Valsartan—Mental disorder—Ramipril—type 2 diabetes mellitus	2.08e-05	0.000656	CcSEcCtD
Valsartan—Infection—Irbesartan—type 2 diabetes mellitus	2.07e-05	0.000655	CcSEcCtD
Valsartan—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	2.07e-05	0.000655	CcSEcCtD
Valsartan—Fatigue—Orlistat—type 2 diabetes mellitus	2.07e-05	0.000654	CcSEcCtD
Valsartan—Hypotension—Metformin—type 2 diabetes mellitus	2.07e-05	0.000653	CcSEcCtD
Valsartan—Malnutrition—Ramipril—type 2 diabetes mellitus	2.06e-05	0.000652	CcSEcCtD
Valsartan—Shock—Irbesartan—type 2 diabetes mellitus	2.05e-05	0.000649	CcSEcCtD
Valsartan—Arthralgia—Losartan—type 2 diabetes mellitus	2.05e-05	0.000648	CcSEcCtD
Valsartan—Chest pain—Losartan—type 2 diabetes mellitus	2.05e-05	0.000648	CcSEcCtD
Valsartan—Myalgia—Losartan—type 2 diabetes mellitus	2.05e-05	0.000648	CcSEcCtD
Valsartan—Vomiting—Bromocriptine—type 2 diabetes mellitus	2.05e-05	0.000647	CcSEcCtD
Valsartan—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	2.05e-05	0.000647	CcSEcCtD
Valsartan—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	2.04e-05	0.000646	CcSEcCtD
Valsartan—Anxiety—Losartan—type 2 diabetes mellitus	2.04e-05	0.000645	CcSEcCtD
Valsartan—Rash—Bromocriptine—type 2 diabetes mellitus	2.03e-05	0.000642	CcSEcCtD
Valsartan—Dermatitis—Bromocriptine—type 2 diabetes mellitus	2.03e-05	0.000641	CcSEcCtD
Valsartan—Skin disorder—Irbesartan—type 2 diabetes mellitus	2.03e-05	0.000641	CcSEcCtD
Valsartan—Dysgeusia—Ramipril—type 2 diabetes mellitus	2.02e-05	0.000639	CcSEcCtD
Valsartan—Headache—Bromocriptine—type 2 diabetes mellitus	2.02e-05	0.000638	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	2.01e-05	0.000637	CcSEcCtD
Valsartan—Diarrhoea—Glyburide—type 2 diabetes mellitus	2.01e-05	0.000637	CcSEcCtD
Valsartan—Dry mouth—Losartan—type 2 diabetes mellitus	2e-05	0.000633	CcSEcCtD
Valsartan—Anorexia—Irbesartan—type 2 diabetes mellitus	1.99e-05	0.000629	CcSEcCtD
Valsartan—Paraesthesia—Metformin—type 2 diabetes mellitus	1.99e-05	0.000628	CcSEcCtD
Valsartan—Muscle spasms—Ramipril—type 2 diabetes mellitus	1.98e-05	0.000627	CcSEcCtD
Valsartan—Dyspnoea—Metformin—type 2 diabetes mellitus	1.97e-05	0.000623	CcSEcCtD
Valsartan—Somnolence—Metformin—type 2 diabetes mellitus	1.97e-05	0.000621	CcSEcCtD
Valsartan—Oedema—Losartan—type 2 diabetes mellitus	1.96e-05	0.000621	CcSEcCtD
Valsartan—Anaphylactic shock—Losartan—type 2 diabetes mellitus	1.96e-05	0.000621	CcSEcCtD
Valsartan—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	1.96e-05	0.00062	CcSEcCtD
Valsartan—Infection—Losartan—type 2 diabetes mellitus	1.95e-05	0.000617	CcSEcCtD
Valsartan—Hypotension—Irbesartan—type 2 diabetes mellitus	1.95e-05	0.000616	CcSEcCtD
Valsartan—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	1.95e-05	0.000615	CcSEcCtD
Valsartan—Dyspepsia—Metformin—type 2 diabetes mellitus	1.95e-05	0.000615	CcSEcCtD
Valsartan—Shock—Losartan—type 2 diabetes mellitus	1.93e-05	0.000611	CcSEcCtD
Valsartan—Nervous system disorder—Losartan—type 2 diabetes mellitus	1.93e-05	0.000609	CcSEcCtD
Valsartan—Thrombocytopenia—Losartan—type 2 diabetes mellitus	1.92e-05	0.000608	CcSEcCtD
Valsartan—Decreased appetite—Metformin—type 2 diabetes mellitus	1.92e-05	0.000608	CcSEcCtD
Valsartan—Nausea—Bromocriptine—type 2 diabetes mellitus	1.91e-05	0.000605	CcSEcCtD
Valsartan—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	1.91e-05	0.000603	CcSEcCtD
Valsartan—Fatigue—Metformin—type 2 diabetes mellitus	1.91e-05	0.000603	CcSEcCtD
Valsartan—Urticaria—Orlistat—type 2 diabetes mellitus	1.91e-05	0.000603	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	1.9e-05	0.000601	CcSEcCtD
Valsartan—Abdominal pain—Orlistat—type 2 diabetes mellitus	1.9e-05	0.0006	CcSEcCtD
Valsartan—Asthenia—Gliclazide—type 2 diabetes mellitus	1.9e-05	0.000599	CcSEcCtD
Valsartan—Constipation—Metformin—type 2 diabetes mellitus	1.89e-05	0.000598	CcSEcCtD
Valsartan—Angioedema—Ramipril—type 2 diabetes mellitus	1.89e-05	0.000596	CcSEcCtD
Valsartan—Paraesthesia—Irbesartan—type 2 diabetes mellitus	1.87e-05	0.000592	CcSEcCtD
Valsartan—Anorexia—Losartan—type 2 diabetes mellitus	1.87e-05	0.000592	CcSEcCtD
Valsartan—Vomiting—Glyburide—type 2 diabetes mellitus	1.87e-05	0.000592	CcSEcCtD
Valsartan—Pruritus—Gliclazide—type 2 diabetes mellitus	1.87e-05	0.000591	CcSEcCtD
Valsartan—Dyspnoea—Irbesartan—type 2 diabetes mellitus	1.86e-05	0.000588	CcSEcCtD
Valsartan—Rash—Glyburide—type 2 diabetes mellitus	1.86e-05	0.000587	CcSEcCtD
Valsartan—Somnolence—Irbesartan—type 2 diabetes mellitus	1.85e-05	0.000586	CcSEcCtD
Valsartan—Dermatitis—Glyburide—type 2 diabetes mellitus	1.85e-05	0.000586	CcSEcCtD
Valsartan—Vertigo—Ramipril—type 2 diabetes mellitus	1.85e-05	0.000586	CcSEcCtD
Valsartan—Syncope—Ramipril—type 2 diabetes mellitus	1.85e-05	0.000585	CcSEcCtD
Valsartan—Headache—Glyburide—type 2 diabetes mellitus	1.84e-05	0.000583	CcSEcCtD
Valsartan—Dyspepsia—Irbesartan—type 2 diabetes mellitus	1.84e-05	0.000581	CcSEcCtD
Valsartan—Hypotension—Losartan—type 2 diabetes mellitus	1.83e-05	0.00058	CcSEcCtD
Valsartan—Palpitations—Ramipril—type 2 diabetes mellitus	1.82e-05	0.000576	CcSEcCtD
Valsartan—Decreased appetite—Irbesartan—type 2 diabetes mellitus	1.81e-05	0.000573	CcSEcCtD
Valsartan—Loss of consciousness—Ramipril—type 2 diabetes mellitus	1.81e-05	0.000573	CcSEcCtD
Valsartan—Diarrhoea—Gliclazide—type 2 diabetes mellitus	1.81e-05	0.000572	CcSEcCtD
Valsartan—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	1.81e-05	0.000572	CcSEcCtD
Valsartan—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	1.8e-05	0.000569	CcSEcCtD
Valsartan—Cough—Ramipril—type 2 diabetes mellitus	1.8e-05	0.000569	CcSEcCtD
Valsartan—Fatigue—Irbesartan—type 2 diabetes mellitus	1.8e-05	0.000569	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	1.79e-05	0.000566	CcSEcCtD
Valsartan—Constipation—Irbesartan—type 2 diabetes mellitus	1.78e-05	0.000564	CcSEcCtD
Valsartan—Losartan—CYP3A4—type 2 diabetes mellitus	1.78e-05	0.02	CrCbGaD
Valsartan—Insomnia—Losartan—type 2 diabetes mellitus	1.78e-05	0.000561	CcSEcCtD
Valsartan—Hypersensitivity—Orlistat—type 2 diabetes mellitus	1.77e-05	0.000559	CcSEcCtD
Valsartan—Paraesthesia—Losartan—type 2 diabetes mellitus	1.76e-05	0.000557	CcSEcCtD
Valsartan—Urticaria—Metformin—type 2 diabetes mellitus	1.76e-05	0.000555	CcSEcCtD
Valsartan—Chest pain—Ramipril—type 2 diabetes mellitus	1.76e-05	0.000555	CcSEcCtD
Valsartan—Myalgia—Ramipril—type 2 diabetes mellitus	1.76e-05	0.000555	CcSEcCtD
Valsartan—Arthralgia—Ramipril—type 2 diabetes mellitus	1.76e-05	0.000555	CcSEcCtD
Valsartan—Dyspnoea—Losartan—type 2 diabetes mellitus	1.75e-05	0.000553	CcSEcCtD
Valsartan—Anxiety—Ramipril—type 2 diabetes mellitus	1.75e-05	0.000553	CcSEcCtD
Valsartan—Nausea—Glyburide—type 2 diabetes mellitus	1.75e-05	0.000553	CcSEcCtD
Valsartan—Abdominal pain—Metformin—type 2 diabetes mellitus	1.75e-05	0.000553	CcSEcCtD
Valsartan—Dizziness—Gliclazide—type 2 diabetes mellitus	1.75e-05	0.000552	CcSEcCtD
Valsartan—Somnolence—Losartan—type 2 diabetes mellitus	1.75e-05	0.000552	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	1.74e-05	0.000551	CcSEcCtD
Valsartan—Dyspepsia—Losartan—type 2 diabetes mellitus	1.73e-05	0.000546	CcSEcCtD
Valsartan—Asthenia—Orlistat—type 2 diabetes mellitus	1.72e-05	0.000544	CcSEcCtD
Valsartan—Dry mouth—Ramipril—type 2 diabetes mellitus	1.72e-05	0.000543	CcSEcCtD
Valsartan—Decreased appetite—Losartan—type 2 diabetes mellitus	1.71e-05	0.00054	CcSEcCtD
Valsartan—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	1.71e-05	0.000539	CcSEcCtD
Valsartan—Pruritus—Orlistat—type 2 diabetes mellitus	1.7e-05	0.000537	CcSEcCtD
Valsartan—Fatigue—Losartan—type 2 diabetes mellitus	1.69e-05	0.000535	CcSEcCtD
Valsartan—Oedema—Ramipril—type 2 diabetes mellitus	1.68e-05	0.000532	CcSEcCtD
Valsartan—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	1.68e-05	0.000532	CcSEcCtD
Valsartan—Vomiting—Gliclazide—type 2 diabetes mellitus	1.68e-05	0.000531	CcSEcCtD
Valsartan—Constipation—Losartan—type 2 diabetes mellitus	1.68e-05	0.000531	CcSEcCtD
Valsartan—Rash—Gliclazide—type 2 diabetes mellitus	1.67e-05	0.000527	CcSEcCtD
Valsartan—Dermatitis—Gliclazide—type 2 diabetes mellitus	1.66e-05	0.000526	CcSEcCtD
Valsartan—Urticaria—Irbesartan—type 2 diabetes mellitus	1.66e-05	0.000524	CcSEcCtD
Valsartan—Shock—Ramipril—type 2 diabetes mellitus	1.66e-05	0.000524	CcSEcCtD
Valsartan—Headache—Gliclazide—type 2 diabetes mellitus	1.66e-05	0.000523	CcSEcCtD
Valsartan—Nervous system disorder—Ramipril—type 2 diabetes mellitus	1.65e-05	0.000522	CcSEcCtD
Valsartan—Abdominal pain—Irbesartan—type 2 diabetes mellitus	1.65e-05	0.000521	CcSEcCtD
Valsartan—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	1.65e-05	0.000521	CcSEcCtD
Valsartan—Diarrhoea—Orlistat—type 2 diabetes mellitus	1.64e-05	0.000519	CcSEcCtD
Valsartan—Skin disorder—Ramipril—type 2 diabetes mellitus	1.64e-05	0.000517	CcSEcCtD
Valsartan—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	1.61e-05	0.000508	CcSEcCtD
Valsartan—Anorexia—Ramipril—type 2 diabetes mellitus	1.6e-05	0.000507	CcSEcCtD
Valsartan—Dizziness—Orlistat—type 2 diabetes mellitus	1.59e-05	0.000502	CcSEcCtD
Valsartan—Asthenia—Metformin—type 2 diabetes mellitus	1.59e-05	0.000501	CcSEcCtD
Valsartan—Hypotension—Ramipril—type 2 diabetes mellitus	1.57e-05	0.000497	CcSEcCtD
Valsartan—Nausea—Gliclazide—type 2 diabetes mellitus	1.57e-05	0.000496	CcSEcCtD
Valsartan—Pruritus—Metformin—type 2 diabetes mellitus	1.56e-05	0.000495	CcSEcCtD
Valsartan—Urticaria—Losartan—type 2 diabetes mellitus	1.56e-05	0.000493	CcSEcCtD
Valsartan—Abdominal pain—Losartan—type 2 diabetes mellitus	1.55e-05	0.000491	CcSEcCtD
Valsartan—Losartan—ALB—type 2 diabetes mellitus	1.55e-05	0.0175	CrCbGaD
Valsartan—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	1.54e-05	0.000486	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	1.53e-05	0.000485	CcSEcCtD
Valsartan—Vomiting—Orlistat—type 2 diabetes mellitus	1.53e-05	0.000482	CcSEcCtD
Valsartan—Insomnia—Ramipril—type 2 diabetes mellitus	1.52e-05	0.000481	CcSEcCtD
Valsartan—Diarrhoea—Metformin—type 2 diabetes mellitus	1.51e-05	0.000478	CcSEcCtD
Valsartan—Rash—Orlistat—type 2 diabetes mellitus	1.51e-05	0.000478	CcSEcCtD
Valsartan—Paraesthesia—Ramipril—type 2 diabetes mellitus	1.51e-05	0.000478	CcSEcCtD
Valsartan—Dermatitis—Orlistat—type 2 diabetes mellitus	1.51e-05	0.000478	CcSEcCtD
Valsartan—Headache—Orlistat—type 2 diabetes mellitus	1.5e-05	0.000475	CcSEcCtD
Valsartan—Dyspnoea—Ramipril—type 2 diabetes mellitus	1.5e-05	0.000475	CcSEcCtD
Valsartan—Asthenia—Irbesartan—type 2 diabetes mellitus	1.5e-05	0.000473	CcSEcCtD
Valsartan—Somnolence—Ramipril—type 2 diabetes mellitus	1.5e-05	0.000473	CcSEcCtD
Valsartan—Dyspepsia—Ramipril—type 2 diabetes mellitus	1.48e-05	0.000469	CcSEcCtD
Valsartan—Pruritus—Irbesartan—type 2 diabetes mellitus	1.48e-05	0.000467	CcSEcCtD
Valsartan—Decreased appetite—Ramipril—type 2 diabetes mellitus	1.46e-05	0.000463	CcSEcCtD
Valsartan—Dizziness—Metformin—type 2 diabetes mellitus	1.46e-05	0.000462	CcSEcCtD
Valsartan—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	1.45e-05	0.00046	CcSEcCtD
Valsartan—Fatigue—Ramipril—type 2 diabetes mellitus	1.45e-05	0.000459	CcSEcCtD
Valsartan—CYP2C9—liver—type 2 diabetes mellitus	1.45e-05	0.0203	CbGeAlD
Valsartan—Hypersensitivity—Losartan—type 2 diabetes mellitus	1.45e-05	0.000457	CcSEcCtD
Valsartan—Constipation—Ramipril—type 2 diabetes mellitus	1.44e-05	0.000455	CcSEcCtD
Valsartan—Diarrhoea—Irbesartan—type 2 diabetes mellitus	1.43e-05	0.000451	CcSEcCtD
Valsartan—Nausea—Orlistat—type 2 diabetes mellitus	1.43e-05	0.00045	CcSEcCtD
Valsartan—Asthenia—Losartan—type 2 diabetes mellitus	1.41e-05	0.000445	CcSEcCtD
Valsartan—Vomiting—Metformin—type 2 diabetes mellitus	1.41e-05	0.000444	CcSEcCtD
Valsartan—Rash—Metformin—type 2 diabetes mellitus	1.39e-05	0.000441	CcSEcCtD
Valsartan—Dermatitis—Metformin—type 2 diabetes mellitus	1.39e-05	0.00044	CcSEcCtD
Valsartan—Pruritus—Losartan—type 2 diabetes mellitus	1.39e-05	0.000439	CcSEcCtD
Valsartan—Headache—Metformin—type 2 diabetes mellitus	1.39e-05	0.000438	CcSEcCtD
Valsartan—Dizziness—Irbesartan—type 2 diabetes mellitus	1.38e-05	0.000436	CcSEcCtD
Valsartan—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	1.38e-05	0.000435	CcSEcCtD
Valsartan—Diarrhoea—Losartan—type 2 diabetes mellitus	1.34e-05	0.000425	CcSEcCtD
Valsartan—Urticaria—Ramipril—type 2 diabetes mellitus	1.34e-05	0.000423	CcSEcCtD
Valsartan—Abdominal pain—Ramipril—type 2 diabetes mellitus	1.33e-05	0.000421	CcSEcCtD
Valsartan—Vomiting—Irbesartan—type 2 diabetes mellitus	1.33e-05	0.000419	CcSEcCtD
Valsartan—Rash—Irbesartan—type 2 diabetes mellitus	1.32e-05	0.000416	CcSEcCtD
Valsartan—Dermatitis—Irbesartan—type 2 diabetes mellitus	1.31e-05	0.000416	CcSEcCtD
Valsartan—Nausea—Metformin—type 2 diabetes mellitus	1.31e-05	0.000415	CcSEcCtD
Valsartan—Headache—Irbesartan—type 2 diabetes mellitus	1.31e-05	0.000413	CcSEcCtD
Valsartan—Dizziness—Losartan—type 2 diabetes mellitus	1.3e-05	0.00041	CcSEcCtD
Valsartan—Vomiting—Losartan—type 2 diabetes mellitus	1.25e-05	0.000395	CcSEcCtD
Valsartan—Hypersensitivity—Ramipril—type 2 diabetes mellitus	1.24e-05	0.000392	CcSEcCtD
Valsartan—Nausea—Irbesartan—type 2 diabetes mellitus	1.24e-05	0.000392	CcSEcCtD
Valsartan—Rash—Losartan—type 2 diabetes mellitus	1.24e-05	0.000391	CcSEcCtD
Valsartan—Dermatitis—Losartan—type 2 diabetes mellitus	1.24e-05	0.000391	CcSEcCtD
Valsartan—Headache—Losartan—type 2 diabetes mellitus	1.23e-05	0.000389	CcSEcCtD
Valsartan—Asthenia—Ramipril—type 2 diabetes mellitus	1.21e-05	0.000382	CcSEcCtD
Valsartan—Pruritus—Ramipril—type 2 diabetes mellitus	1.19e-05	0.000377	CcSEcCtD
Valsartan—Nausea—Losartan—type 2 diabetes mellitus	1.17e-05	0.000369	CcSEcCtD
Valsartan—Diarrhoea—Ramipril—type 2 diabetes mellitus	1.15e-05	0.000364	CcSEcCtD
Valsartan—Dizziness—Ramipril—type 2 diabetes mellitus	1.11e-05	0.000352	CcSEcCtD
Valsartan—Vomiting—Ramipril—type 2 diabetes mellitus	1.07e-05	0.000338	CcSEcCtD
Valsartan—Rash—Ramipril—type 2 diabetes mellitus	1.06e-05	0.000336	CcSEcCtD
Valsartan—Dermatitis—Ramipril—type 2 diabetes mellitus	1.06e-05	0.000335	CcSEcCtD
Valsartan—Headache—Ramipril—type 2 diabetes mellitus	1.05e-05	0.000333	CcSEcCtD
Valsartan—Nausea—Ramipril—type 2 diabetes mellitus	1e-05	0.000316	CcSEcCtD
Valsartan—ALB—Metabolism—UCP3—type 2 diabetes mellitus	2.59e-06	0.000183	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—OXCT1—type 2 diabetes mellitus	2.55e-06	0.000181	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYTB—type 2 diabetes mellitus	2.55e-06	0.000181	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP2E1—type 2 diabetes mellitus	2.51e-06	0.000178	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—APOB—type 2 diabetes mellitus	2.51e-06	0.000178	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—MTHFR—type 2 diabetes mellitus	2.5e-06	0.000177	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—GNB3—type 2 diabetes mellitus	2.5e-06	0.000177	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CD36—type 2 diabetes mellitus	2.5e-06	0.000177	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	2.5e-06	0.000177	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SRD5A1—type 2 diabetes mellitus	2.49e-06	0.000176	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—HMOX1—type 2 diabetes mellitus	2.49e-06	0.000176	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP1A2—type 2 diabetes mellitus	2.48e-06	0.000176	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—SLC2A1—type 2 diabetes mellitus	2.48e-06	0.000176	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PPP2CA—type 2 diabetes mellitus	2.47e-06	0.000175	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—AVP—type 2 diabetes mellitus	2.47e-06	0.000175	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PPARA—type 2 diabetes mellitus	2.45e-06	0.000174	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCR5—type 2 diabetes mellitus	2.45e-06	0.000174	CbGpPWpGaD
Valsartan—ALB—Metabolism—PCK1—type 2 diabetes mellitus	2.43e-06	0.000172	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP3A4—type 2 diabetes mellitus	2.42e-06	0.000171	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	2.41e-06	0.00017	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—C3—type 2 diabetes mellitus	2.4e-06	0.00017	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—LPL—type 2 diabetes mellitus	2.39e-06	0.00017	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—APOB—type 2 diabetes mellitus	2.38e-06	0.000169	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—SLC2A4—type 2 diabetes mellitus	2.38e-06	0.000168	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GCG—type 2 diabetes mellitus	2.38e-06	0.000168	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AGT—type 2 diabetes mellitus	2.38e-06	0.000168	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HSD17B3—type 2 diabetes mellitus	2.37e-06	0.000168	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—STAR—type 2 diabetes mellitus	2.37e-06	0.000168	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ACACA—type 2 diabetes mellitus	2.37e-06	0.000168	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—SRC—type 2 diabetes mellitus	2.37e-06	0.000168	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CALM1—type 2 diabetes mellitus	2.34e-06	0.000165	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—GPX1—type 2 diabetes mellitus	2.34e-06	0.000165	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—APOE—type 2 diabetes mellitus	2.33e-06	0.000165	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—VEGFA—type 2 diabetes mellitus	2.31e-06	0.000163	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—APOA1—type 2 diabetes mellitus	2.3e-06	0.000163	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	2.28e-06	0.000162	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IRS2—type 2 diabetes mellitus	2.28e-06	0.000161	CbGpPWpGaD
Valsartan—ALB—Hemostasis—MMP1—type 2 diabetes mellitus	2.28e-06	0.000161	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CBS—type 2 diabetes mellitus	2.28e-06	0.000161	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCC8—type 2 diabetes mellitus	2.28e-06	0.000161	CbGpPWpGaD
Valsartan—ALB—Metabolism—HK1—type 2 diabetes mellitus	2.28e-06	0.000161	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AGT—type 2 diabetes mellitus	2.28e-06	0.000161	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CD36—type 2 diabetes mellitus	2.27e-06	0.000161	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CALM1—type 2 diabetes mellitus	2.24e-06	0.000159	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APOE—type 2 diabetes mellitus	2.23e-06	0.000158	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—LEP—type 2 diabetes mellitus	2.23e-06	0.000158	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—ADCY5—type 2 diabetes mellitus	2.23e-06	0.000158	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CALM1—type 2 diabetes mellitus	2.21e-06	0.000157	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APOA1—type 2 diabetes mellitus	2.2e-06	0.000156	CbGpPWpGaD
Valsartan—ALB—Metabolism—KCNJ11—type 2 diabetes mellitus	2.2e-06	0.000156	CbGpPWpGaD
Valsartan—ALB—Metabolism—GCKR—type 2 diabetes mellitus	2.2e-06	0.000156	CbGpPWpGaD
Valsartan—ALB—Metabolism—HSD3B2—type 2 diabetes mellitus	2.2e-06	0.000156	CbGpPWpGaD
Valsartan—ALB—Metabolism—LPA—type 2 diabetes mellitus	2.2e-06	0.000156	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—COX2—type 2 diabetes mellitus	2.19e-06	0.000155	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC5A2—type 2 diabetes mellitus	2.19e-06	0.000155	CbGpPWpGaD
Valsartan—ALB—Hemostasis—APOA1—type 2 diabetes mellitus	2.18e-06	0.000154	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NCOA6—type 2 diabetes mellitus	2.15e-06	0.000152	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARGC1A—type 2 diabetes mellitus	2.15e-06	0.000152	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—TGFB1—type 2 diabetes mellitus	2.12e-06	0.00015	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HSD11B1—type 2 diabetes mellitus	2.12e-06	0.00015	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—UCP2—type 2 diabetes mellitus	2.12e-06	0.00015	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—UCP3—type 2 diabetes mellitus	2.12e-06	0.00015	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PPARA—type 2 diabetes mellitus	2.11e-06	0.00015	CbGpPWpGaD
Valsartan—ALB—Metabolism—ALDOB—type 2 diabetes mellitus	2.11e-06	0.000149	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	2.1e-06	0.000149	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PRKCB—type 2 diabetes mellitus	2.08e-06	0.000147	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NOS2—type 2 diabetes mellitus	2.05e-06	0.000145	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOB—type 2 diabetes mellitus	2.05e-06	0.000145	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.05e-06	0.000145	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GNB3—type 2 diabetes mellitus	2.05e-06	0.000145	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—AGT—type 2 diabetes mellitus	2.05e-06	0.000145	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—HMOX1—type 2 diabetes mellitus	2.04e-06	0.000144	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PPARG—type 2 diabetes mellitus	2.03e-06	0.000144	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CAT—type 2 diabetes mellitus	2.01e-06	0.000143	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—PPARA—type 2 diabetes mellitus	2.01e-06	0.000142	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—APOE—type 2 diabetes mellitus	2.01e-06	0.000142	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PCK1—type 2 diabetes mellitus	1.99e-06	0.000141	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.99e-06	0.000141	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—INS—type 2 diabetes mellitus	1.99e-06	0.000141	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—APOA1—type 2 diabetes mellitus	1.98e-06	0.00014	CbGpPWpGaD
Valsartan—ALB—Metabolism—GLP1R—type 2 diabetes mellitus	1.96e-06	0.000139	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—LPL—type 2 diabetes mellitus	1.96e-06	0.000139	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOB—type 2 diabetes mellitus	1.95e-06	0.000138	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—type 2 diabetes mellitus	1.91e-06	0.000135	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—INS—type 2 diabetes mellitus	1.91e-06	0.000135	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTM1—type 2 diabetes mellitus	1.9e-06	0.000135	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	1.89e-06	0.000134	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.87e-06	0.000133	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—LPL—type 2 diabetes mellitus	1.87e-06	0.000132	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HK1—type 2 diabetes mellitus	1.86e-06	0.000132	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CD36—type 2 diabetes mellitus	1.86e-06	0.000132	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.84e-06	0.000131	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.84e-06	0.00013	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.83e-06	0.00013	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC2A2—type 2 diabetes mellitus	1.83e-06	0.00013	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ADCY5—type 2 diabetes mellitus	1.83e-06	0.000129	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ALB—type 2 diabetes mellitus	1.82e-06	0.000129	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IGF1—type 2 diabetes mellitus	1.82e-06	0.000129	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GPX1—type 2 diabetes mellitus	1.82e-06	0.000129	CbGpPWpGaD
Valsartan—ALB—Hemostasis—AKT2—type 2 diabetes mellitus	1.82e-06	0.000129	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HSD3B2—type 2 diabetes mellitus	1.8e-06	0.000127	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—KCNJ11—type 2 diabetes mellitus	1.8e-06	0.000127	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GCKR—type 2 diabetes mellitus	1.8e-06	0.000127	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LPA—type 2 diabetes mellitus	1.8e-06	0.000127	CbGpPWpGaD
Valsartan—ALB—Metabolism—MTR—type 2 diabetes mellitus	1.79e-06	0.000127	CbGpPWpGaD
Valsartan—ALB—Metabolism—CPT1A—type 2 diabetes mellitus	1.79e-06	0.000127	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CD36—type 2 diabetes mellitus	1.77e-06	0.000126	CbGpPWpGaD
Valsartan—ALB—Metabolism—NAMPT—type 2 diabetes mellitus	1.76e-06	0.000124	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPP2CA—type 2 diabetes mellitus	1.75e-06	0.000124	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.75e-06	0.000124	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	1.75e-06	0.000124	CbGpPWpGaD
Valsartan—ALB—Metabolism—LIPC—type 2 diabetes mellitus	1.75e-06	0.000124	CbGpPWpGaD
Valsartan—ALB—Metabolism—GCK—type 2 diabetes mellitus	1.75e-06	0.000124	CbGpPWpGaD
Valsartan—ALB—Metabolism—HBA1—type 2 diabetes mellitus	1.75e-06	0.000124	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3R1—type 2 diabetes mellitus	1.74e-06	0.000123	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—NOS3—type 2 diabetes mellitus	1.74e-06	0.000123	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP11A1—type 2 diabetes mellitus	1.74e-06	0.000123	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—type 2 diabetes mellitus	1.73e-06	0.000123	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SERPINE1—type 2 diabetes mellitus	1.73e-06	0.000122	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALDOB—type 2 diabetes mellitus	1.73e-06	0.000122	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC9A1—type 2 diabetes mellitus	1.7e-06	0.000121	CbGpPWpGaD
Valsartan—ALB—Metabolism—CETP—type 2 diabetes mellitus	1.69e-06	0.000119	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—MTHFR—type 2 diabetes mellitus	1.68e-06	0.000119	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—AGT—type 2 diabetes mellitus	1.68e-06	0.000119	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.67e-06	0.000118	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.67e-06	0.000118	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3R1—type 2 diabetes mellitus	1.65e-06	0.000117	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NOS3—type 2 diabetes mellitus	1.65e-06	0.000117	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARA—type 2 diabetes mellitus	1.65e-06	0.000117	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—type 2 diabetes mellitus	1.64e-06	0.000116	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—type 2 diabetes mellitus	1.62e-06	0.000115	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GLP1R—type 2 diabetes mellitus	1.6e-06	0.000114	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AGT—type 2 diabetes mellitus	1.6e-06	0.000113	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTGS2—type 2 diabetes mellitus	1.59e-06	0.000113	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.57e-06	0.000111	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CALM1—type 2 diabetes mellitus	1.57e-06	0.000111	CbGpPWpGaD
Valsartan—ALB—Metabolism—SNAP25—type 2 diabetes mellitus	1.57e-06	0.000111	CbGpPWpGaD
Valsartan—ALB—Metabolism—SREBF1—type 2 diabetes mellitus	1.57e-06	0.000111	CbGpPWpGaD
Valsartan—ALB—Metabolism—PSMD6—type 2 diabetes mellitus	1.57e-06	0.000111	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOE—type 2 diabetes mellitus	1.56e-06	0.000111	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOA1—type 2 diabetes mellitus	1.55e-06	0.000109	CbGpPWpGaD
Valsartan—ALB—Metabolism—CTGF—type 2 diabetes mellitus	1.54e-06	0.000109	CbGpPWpGaD
Valsartan—ALB—Metabolism—HMGCR—type 2 diabetes mellitus	1.52e-06	0.000108	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	1.5e-06	0.000106	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC2A2—type 2 diabetes mellitus	1.5e-06	0.000106	CbGpPWpGaD
Valsartan—ALB—Metabolism—ADRA2A—type 2 diabetes mellitus	1.49e-06	0.000106	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—AKT1—type 2 diabetes mellitus	1.47e-06	0.000104	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CPT1A—type 2 diabetes mellitus	1.47e-06	0.000104	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MTR—type 2 diabetes mellitus	1.47e-06	0.000104	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NAMPT—type 2 diabetes mellitus	1.44e-06	0.000102	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP2E1—type 2 diabetes mellitus	1.43e-06	0.000101	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.43e-06	0.000101	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	1.43e-06	0.000101	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LIPC—type 2 diabetes mellitus	1.43e-06	0.000101	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HBA1—type 2 diabetes mellitus	1.43e-06	0.000101	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GCK—type 2 diabetes mellitus	1.43e-06	0.000101	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP11A1—type 2 diabetes mellitus	1.42e-06	0.000101	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.42e-06	0.0001	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP1A2—type 2 diabetes mellitus	1.42e-06	0.0001	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC2A1—type 2 diabetes mellitus	1.42e-06	0.0001	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.41e-06	9.98e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC9A1—type 2 diabetes mellitus	1.4e-06	9.88e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP3A4—type 2 diabetes mellitus	1.38e-06	9.79e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CETP—type 2 diabetes mellitus	1.38e-06	9.77e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	1.37e-06	9.74e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARG—type 2 diabetes mellitus	1.36e-06	9.65e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GCG—type 2 diabetes mellitus	1.36e-06	9.62e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC2A4—type 2 diabetes mellitus	1.36e-06	9.62e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.34e-06	9.49e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—INS—type 2 diabetes mellitus	1.34e-06	9.46e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.33e-06	9.39e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.3e-06	9.21e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	1.29e-06	9.11e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PSMD6—type 2 diabetes mellitus	1.28e-06	9.08e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SNAP25—type 2 diabetes mellitus	1.28e-06	9.08e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SREBF1—type 2 diabetes mellitus	1.28e-06	9.08e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CTGF—type 2 diabetes mellitus	1.26e-06	8.91e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HMGCR—type 2 diabetes mellitus	1.25e-06	8.84e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.24e-06	8.75e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	1.23e-06	8.71e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ALB—type 2 diabetes mellitus	1.22e-06	8.67e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SRC—type 2 diabetes mellitus	1.22e-06	8.65e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ADRA2A—type 2 diabetes mellitus	1.22e-06	8.65e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.2e-06	8.53e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—VEGFA—type 2 diabetes mellitus	1.19e-06	8.42e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP2E1—type 2 diabetes mellitus	1.17e-06	8.31e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.17e-06	8.3e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NOS3—type 2 diabetes mellitus	1.17e-06	8.3e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.17e-06	8.29e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GNB3—type 2 diabetes mellitus	1.17e-06	8.29e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—HMOX1—type 2 diabetes mellitus	1.17e-06	8.25e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC2A1—type 2 diabetes mellitus	1.16e-06	8.21e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP1A2—type 2 diabetes mellitus	1.16e-06	8.21e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CAT—type 2 diabetes mellitus	1.15e-06	8.14e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP3A4—type 2 diabetes mellitus	1.13e-06	8.01e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	1.13e-06	7.97e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOB—type 2 diabetes mellitus	1.12e-06	7.91e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GCG—type 2 diabetes mellitus	1.11e-06	7.87e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC2A4—type 2 diabetes mellitus	1.11e-06	7.87e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.1e-06	7.83e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TGFB1—type 2 diabetes mellitus	1.09e-06	7.73e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTM1—type 2 diabetes mellitus	1.09e-06	7.69e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.08e-06	7.67e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTGS2—type 2 diabetes mellitus	1.07e-06	7.59e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—LPL—type 2 diabetes mellitus	1.07e-06	7.55e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—ADCY5—type 2 diabetes mellitus	1.04e-06	7.39e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GPX1—type 2 diabetes mellitus	1.04e-06	7.37e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CD36—type 2 diabetes mellitus	1.01e-06	7.17e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPP2CA—type 2 diabetes mellitus	1e-06	7.08e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—MTHFR—type 2 diabetes mellitus	9.6e-07	6.8e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARGC1A—type 2 diabetes mellitus	9.58e-07	6.79e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GNB3—type 2 diabetes mellitus	9.58e-07	6.79e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HMOX1—type 2 diabetes mellitus	9.54e-07	6.76e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARA—type 2 diabetes mellitus	9.42e-07	6.67e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CAT—type 2 diabetes mellitus	9.41e-07	6.67e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOB—type 2 diabetes mellitus	9.14e-07	6.47e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—AGT—type 2 diabetes mellitus	9.12e-07	6.46e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CALM1—type 2 diabetes mellitus	8.97e-07	6.35e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOE—type 2 diabetes mellitus	8.93e-07	6.33e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTM1—type 2 diabetes mellitus	8.89e-07	6.3e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOA1—type 2 diabetes mellitus	8.83e-07	6.26e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LPL—type 2 diabetes mellitus	8.72e-07	6.18e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ADCY5—type 2 diabetes mellitus	8.54e-07	6.05e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GPX1—type 2 diabetes mellitus	8.51e-07	6.03e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6—type 2 diabetes mellitus	8.33e-07	5.9e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CD36—type 2 diabetes mellitus	8.29e-07	5.87e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPP2CA—type 2 diabetes mellitus	8.19e-07	5.8e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AKT1—type 2 diabetes mellitus	8.02e-07	5.68e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MTHFR—type 2 diabetes mellitus	7.86e-07	5.56e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARG—type 2 diabetes mellitus	7.78e-07	5.51e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARA—type 2 diabetes mellitus	7.71e-07	5.46e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.68e-07	5.44e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—INS—type 2 diabetes mellitus	7.63e-07	5.41e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—AKT1—type 2 diabetes mellitus	7.59e-07	5.37e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AGT—type 2 diabetes mellitus	7.46e-07	5.29e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CALM1—type 2 diabetes mellitus	7.34e-07	5.2e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOE—type 2 diabetes mellitus	7.31e-07	5.18e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOA1—type 2 diabetes mellitus	7.23e-07	5.12e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3R1—type 2 diabetes mellitus	6.69e-07	4.74e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—NOS3—type 2 diabetes mellitus	6.69e-07	4.74e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARG—type 2 diabetes mellitus	6.37e-07	4.51e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—INS—type 2 diabetes mellitus	6.25e-07	4.42e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTGS2—type 2 diabetes mellitus	6.12e-07	4.34e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALB—type 2 diabetes mellitus	5.73e-07	4.06e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3R1—type 2 diabetes mellitus	5.48e-07	3.88e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NOS3—type 2 diabetes mellitus	5.48e-07	3.88e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AKT1—type 2 diabetes mellitus	5.39e-07	3.81e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTGS2—type 2 diabetes mellitus	5.01e-07	3.55e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—AKT1—type 2 diabetes mellitus	3.08e-07	2.18e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AKT1—type 2 diabetes mellitus	2.52e-07	1.78e-05	CbGpPWpGaD
